Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 9/30/2020 | 6/30/2020 | 3/31/2020 | |
|---|---|---|---|---|
| Market Cap | $916 | $1,528 | $563 | $2,170 |
| - Cash | $386 | $782 | $1,312 | $3 |
| + Debt | $1,260 | $1,336 | $1,216 | $1,218 |
| Enterprise Value | $1,791 | $2,083 | $467 | $3,385 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$476 | -$388 | $424 | -$152 |
| % Margin | – | – | – | – |
| Net Income | -$443 | -$361 | $436 | -$150 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.019 | -0.015 | 0.004 | -0.01 |
| % Growth | -26% | -448.8% | 143% | – |
| Operating Cash Flow | -$338 | -$480 | -$221 | -$94 |
| Capital Expenditures | -$0 | -$3 | $0 | $0 |
| Free Cash Flow | -$338 | -$483 | -$221 | -$94 |